苏为坦滴眼液的替代降眼压作用

Replacing treatment to open angle glaucoma or ocular hypertension with Travoprost eyedrops

目的:在其他降眼压药物眼压控制不佳、或无法耐受其他降眼压药物的原发性开角型青光眼或高眼压症患者中评价苏为坦TM0.04g/L的治疗效果。方法:使用单种或多种降眼压药物后眼压控制不佳,或无法耐受其他降眼压药物的原发性开角型青光眼或高眼压症患者40例61眼,给予苏为坦滴眼液替代治疗。每晚点药1次,每次1滴。将连续点药后1,4,12wk的眼压与基线眼压进行比较研究,同时观察血压、心率等全身及局部副作用及其患者的依从性。结果:使用苏为坦滴眼液后眼压明显下降。连续点药1,4,12wk眼压下降分别为6.78±3.45mmHg,5.92±4.29mmHg,5.88±4.12mmHg,P<0.05;降压有效率分别为97%,93%,92%。用药后1,4,12wk降压效果比较,无统计学差异。用药前后,视力、视野、视乳头杯盘比、血压均无明显改变。不良反应发生率为22%,均为轻度,最主要的不良反应为结膜充血,但不妨碍继续用药。患者依从性好。结论:苏为坦TM0.04g/L滴眼液对治疗其他降眼压药物眼压控制不佳、或无法耐受其他降眼压药物的原发性开角型青光眼或高眼压症患者是有效和安全的。

AIM： To evaluate the efficacy and safety of replacing Treatment of Travoprost eyedrops to the patients with primary open angle glaucoma （POAG） or ocular hypertension, whose intraocular pressure（IOP） could not be reduced to normal by other glaucoma drug, or who were intolerant to other glaucoma drug. METHODS： Forty patients with POAG or ocular hypertension whose intraocular pressure（IOP） could not be lowered to normal by other glaucoma drug, or who were intolerant to other glaucoma drug, were treated with Travoprost eyedrops （0.04g/L）. One drop was instilled to each eye in the evening. Intraocular pressure （IOP） at 1, 4 and 12 weeks after sustained instilling were compared with the baseline. On the other hand, systematic and local adverse effects were also observed. RESULTS： At 1,4,12 weeks after sustained instilling, the range of reduction in IOP were 6.78 ± 3.45mmHg, 5.92 ± 4.29mmHg, 5.88 ±4.12mmHg respectively （P〈0.05） ; the efficiency rates were 97%, 93%, 92% respectively. The difference of decrease range between 1,4,12 weeks after sustained instilling was not significant. The vision, visual field, cup-disc ratio and blood pressure did not change much before and after the medicine was administered. The incidence of adverse effects was 22%. The major adverse effect was conjunctival congestion, but it didn＇t affect continuous medication. CONCLUSION： Travoprost eyedrops reduced IOP significantly in replacing treatment to the patients with POAG or ocular hypertension. It is safe and effective.